Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi-aventis Appeals to IP High Court Claiming Allegra’s Use Patents
December 16, 2011
- Eisai Receives Approval for Halaven in Canada
December 16, 2011
- Shionogi’s Subsidiary Starts Biomarker Discovery Research in the US
December 16, 2011
- ReproCELL to Commercialize World’s 1st iPS Cell-Derived Hepatocytes in April
December 16, 2011
- Janssen Voluntarily Recalls Risperdal Tablet 1 mg
December 15, 2011
- Ibandronate Shows Non-inferiority to Risedronate: Chugai, Taisho
December 15, 2011
- Over 60% of Doctors Support Exclusion of Anticancer Drugs from Current Relief System: CareNet
December 15, 2011
- Ono Enters into Joint Research Agreement with US Company to Discover Antagonists for GPCR Target
December 14, 2011
- MTPC to Seek Strategic Alliance to Expand Generics Business: President Tsuchiya
December 14, 2011
- GSK Submits NDA for Pazopanib in Japan
December 14, 2011
- MTPC to Focus on Development of Global Human Resources
December 14, 2011
- Eisai Files Application for New Aricept Dry Syrup Formulation
December 14, 2011
- SGN-35 for Treatment-naïve Lymphoma to Progress to PIII: Takeda
December 14, 2011
- Substance Patent for Therapeutic Protein Delivery Allowed in US: NanoCarrier
December 14, 2011
- PI/II Results Confirm Safety, Tolerability of Oral Proteasome Inhibitor: Takeda
December 14, 2011
- 86% of Patients Show Objective Responses in PII Trial of CD30 Monoclonal Antibody: Takeda
December 14, 2011
- Mochida Pharmaceutical Grants Rights for Diabetes Treatment to US Merck
December 13, 2011
- Kissei Pharmaceutical to Transfer Marketing Rights for CABASER to Pfizer Japan
December 13, 2011
- Otsuka's US Subsidiary CEO to Become New President, Taiho Pharmaceutical
December 13, 2011
- Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision
December 13, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…